Why Medtronic (MDT) Stock Is Lower Today

NEW YORK (TheStreet) -- Shares of Medtronic Inc.  (MDT) are down -1.63% to $62.19 on heavy trading volume following speculation that the heart rhythm devices maker would bid for the U.K.'s Smith & Nephew (SNN).

Smith & Nephew closed higher today in London and was one of the better performing stocks, but is down -5.32% to $92.10 in New York trading.

Must Read: Warren Buffett's 25 Favorite Growth Stocks

 

TheStreet Ratings team rates MEDTRONIC INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

"We rate MEDTRONIC INC (MDT) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • Despite its growing revenue, the company underperformed as compared with the industry average of 3.3%. Since the same quarter one year prior, revenues slightly increased by 2.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • Net operating cash flow has increased to $1,328.00 million or 11.87% when compared to the same quarter last year. In addition, MEDTRONIC INC has also modestly surpassed the industry average cash flow growth rate of 7.62%.
  • MDT's debt-to-equity ratio of 0.61 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Even though the debt-to-equity ratio shows mixed results, the company's quick ratio of 3.24 is very high and demonstrates very strong liquidity.
  • Compared to where it was a year ago today, the stock is now trading at a higher level, regardless of the company's weak earnings results. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • You can view the full analysis from the report here: MDT Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

These Stocks Are Showing Reversal Patterns

These Stocks Are Showing Reversal Patterns